Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LBH581 · 1 trial · 1 indication
Objective response rate measured according to the RECIST (Response Evaluation Criteria In Solid Tumours).
| Name | Type | Description |
|---|---|---|
| LBH581 | DRUG | 25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days. |
Inclusion Criteria: 1. Histological/cytological diagnosis of SCLC, mixed small and non small cell tumours are excluded 2. ≤ 2 prior chemotherapy lines 3. Progression after, and not during, last previous chemotherapy treatment 4. Age ≥ 18 and ≤ 75 years 5. Life expectancy of at least 3 months 6. ECO...
LBH581 is an investigational small molecule being studied for the treatment of Small Cell Lung Carcinoma. It is in Phase 2 clinical development and has completed one trial in this indication. The drug is not approved and remains under investigation.
LBH581 is being developed by Novartis AG, a pharmaceutical company listed on the stock exchange under the ticker NVS. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Small Cell Lung Carcinoma.
LBH581 is in Phase 2 clinical development. A Phase 2 trial in Small Cell Lung Carcinoma has been completed. The drug is investigational and has not received regulatory approval for any use.
LBH581 has been studied in one clinical trial, identified as NCT01222936, titled 'LBH Phase II in Small Cell Lung Cancer (SCLC)'. This Phase 2 study enrolled 21 participants and was conducted in Germany and Italy. The trial has been completed.
LBH581 is the drug name used in the clinical trial NCT01222936, which is titled 'LBH Phase II in Small Cell Lung Cancer (SCLC)'. The trial refers to the drug as LBH, indicating that LBH581 and LBH are alternative names for the same investigational compound.